Search results
Results from the WOW.Com Content Network
COVID-19 vaccination roll out in AIIMS, New Delhi, India on 16 January 2021. India began its vaccination programme on 16 January 2021, operating 3,006 vaccination centres on the onset. [23] Each vaccination centre will offer either Covishield or Covaxin, but not both. [24] 165,714 people were vaccinated on the first day of availability.
COVID-19 vaccination roll out in AIIMS, New Delhi, India on 16 January 2021. Vaccination in India includes the use of vaccines in Indian public health and the place of vaccines in Indian society, policy, and research.
On 15 April 2021, Delhi Chief Minister Arvind Kejriwal announced a weekend curfew along with tight restrictions on weekdays in order to curb the second wave of COVID-19 infections. On 17 April 2022, Delhi saw a rise in cases, but the positivity rate has relatively reduced from 5.33% to 4.21% [22]
In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing an Indian COVID-19 vaccine. [ 25 ] [ 26 ] In June 2020, the company received permission to conduct Phase I and Phase II human trials of a developmental COVID-19 vaccine codenamed BBV152 , from the ...
If a person was born on January 1, 2020, and Immunization Act specifies vaccine against measles could be received from age 12 months to 24 months, vaccination shall be practiced between December 31, 2020, and December 31, 2021 (not between January 2021 and January 2022.) [33] [34] Some vaccinations are scheduled in line with the school year ...
Vaccine benefits are debated with some urging caution in the choice of vaccines introduced while expanding the immunisation programme, despite overwhelming and widespread documented scientific evidence on the efficacy of vaccines. [6] With these new vaccines, India's UIP will now provide universal and free vaccines against 13 [citation needed ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease. [24]